The poor usability of GEKs may also be reflective in the low uptake of the drug in the diabetes population, where approximately half of persons with diabetes prescribed a GEK decide to continue fulfilling their renewal prescription.13 Furthermore, the overall utilization of glucagon reflects less than one-fifth of the addressable population—for example, those who take insulin and are at risk of clinically significant hypoglycemia. The gene discussed is GCG; the disease is diabetes mellitus.